Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2013 June;54(3) > The Journal of Cardiovascular Surgery 2013 June;54(3):333-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  INNOVATIONS IN DRUG-ELUTING TECHNOLOGY 

The Journal of Cardiovascular Surgery 2013 June;54(3):333-6

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Femoropopliteal in-stent restenosis: review and potential for drug based therapy

Phillips J. 1, Ansel G. 2

1 Cardiology, Internal Medicine Ohio Health Riverside Methodist Hospital Columbus, OH, USA; 2 Cardiology, Internal Medicine Ohio Health Riverside Methodist Hospital Columbus, OH, USA


PDF


Endovascular treatment of symptomatic peripheral arterial disease in the femoropopliteal (FP) artery is fraught with high rates of restenosis. Success of the antiproliferative drug, paclitaxel, in the coronary arteries, has lead to the investigation of paclitaxel in the peripheral arteries to treat restenosis. This article reviews restenosis rates for the major treatment modalities used in the FP segment. Use of drug-elution for restenosis is also reviewed, including the use of drug-eluting balloons and drug-eluting stents.

top of page